Alnylam Pharmaceuticals, Inc.
General ticker "ALNY" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $41.9B (TTM average)
Alnylam Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 61.0%.
Estimated limits based on current volatility of 2.0%: low 456.06$, high 474.83$
Factors to consider:
- Total employees count: 2230 as of 2024
- US accounted for 3.3% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Product commercialization failure, Operational and conduct risks, Labor/talent shortage/retention, Supply chain disruptions, Regulatory and compliance
- Current price 38.9% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [160.97$, 334.93$]
- 2025-12-31 to 2026-12-31 estimated range: [138.87$, 296.64$]
Financial Metrics affecting the ALNY estimates:
- Negative: with PPE of -5998.7 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -0.03 <= 0.33
- Positive: Investing cash flow per share per price, % of -0.38 > -0.66
- Negative: Shareholder equity ratio, % of 1.58 <= 18.93
Short-term ALNY quotes
Long-term ALNY plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $1,037.42MM | $1,828.29MM | $2,248.24MM |
| Operating Expenses | $1,822.49MM | $2,110.47MM | $2,425.13MM |
| Operating Income | $-785.07MM | $-282.18MM | $-176.88MM |
| Non-Operating Income | $-341.92MM | $-151.34MM | $-200.49MM |
| Interest Expense | $155.97MM | $121.22MM | $141.86MM |
| R&D Expense | $883.01MM | $1,004.41MM | $1,126.23MM |
| Income(Loss) | $-1,126.99MM | $-433.52MM | $-377.38MM |
| Taxes | $4.16MM | $6.72MM | $-99.22MM |
| Profit(Loss)* | $-1,131.16MM | $-440.24MM | $-278.16MM |
| Stockholders Equity | $-158.22MM | $-220.64MM | $67.09MM |
| Inventory | $128.96MM | $89.15MM | $78.51MM |
| Assets | $3,546.36MM | $3,829.88MM | $4,239.98MM |
| Operating Cash Flow | $-541.27MM | $104.16MM | $-8.31MM |
| Capital expenditure | $72.06MM | $62.21MM | $34.28MM |
| Investing Cash Flow | $169.35MM | $-336.35MM | $-116.84MM |
| Financing Cash Flow | $425.75MM | $172.13MM | $294.16MM |
| Earnings Per Share** | $-9.30 | $-3.52 | $-2.18 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.